Hans van Houte, CFO of Nurix Therapeutics ($NRIX), made eight open market sales of company stock over the past year, totaling about $389 thousand. His latest sale occurred on January 30, 2026. These transactions rank 7,004th among 11,678 insiders by sale value, below the average of $8.6 million across 6.4 trades per person. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 10, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Employee Stock Option (right to buy) | 93750 | $0.00 | 93,750.0000 | 102,843,012 | 9999.99% | 0.09% |
| Feb. 10, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Restricted Stock Units | 42875 | $0.00 | 42,875.0000 | 102,843,012 | 9999.99% | 0.04% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 2,000.0000 | 102,843,012 | 50.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 18,750.0000 | 102,843,012 | 16.67% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2859 | $0.00 | 25,725.0000 | 102,843,012 | 10.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 73 | $17.37 | 45,427.0000 | 102,843,012 | 0.16% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2887 | $0.00 | 0.0000 | 102,843,012 | 100.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2887 | $0.00 | 40,479.0000 | 102,843,012 | 7.68% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 42,479.0000 | 102,843,012 | 4.94% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 46,229.0000 | 102,843,012 | 8.83% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2859 | $0.00 | 49,088.0000 | 102,843,012 | 6.18% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3588 | $16.58 | 45,500.0000 | 102,843,012 | 7.31% | 0.00% |
| Nov. 3, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 6284 | $12.56 | 37,592.0000 | 76,883,436 | 14.32% | 0.01% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 2,887.0000 | 76,883,436 | 49.99% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 4,000.0000 | 76,883,436 | 33.33% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 22,500.0000 | 76,883,436 | 14.29% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2858 | $0.00 | 28,584.0000 | 76,883,436 | 9.09% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2858 | $0.00 | 47,006.0000 | 76,883,436 | 6.47% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3130 | $12.80 | 43,876.0000 | 76,883,436 | 6.66% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 38,398.0000 | 76,883,436 | 8.13% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 40,398.0000 | 76,883,436 | 5.21% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 44,148.0000 | 76,883,436 | 9.28% | 0.00% |
| Aug. 1, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 5402 | $11.03 | 35,512.0000 | 75,886,817 | 13.20% | 0.01% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 6,000.0000 | 75,886,817 | 25.00% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 38,610.0000 | 75,886,817 | 5.46% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 42,360.0000 | 75,886,817 | 9.71% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2858 | $0.00 | 45,218.0000 | 75,886,817 | 6.75% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 4304 | $12.01 | 40,914.0000 | 75,886,817 | 9.52% | 0.01% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 5,773.0000 | 75,886,817 | 33.33% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 26,250.0000 | 75,886,817 | 12.50% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2858 | $0.00 | 31,442.0000 | 75,886,817 | 8.33% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 36,610.0000 | 75,886,817 | 8.56% | 0.00% |
| May 2, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 6198 | $11.33 | 33,724.0000 | 75,886,817 | 15.53% | 0.01% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 8,000.0000 | 75,886,817 | 20.00% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 8,659.0000 | 75,886,817 | 25.00% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 2438 | $11.50 | 39,922.0000 | 75,886,817 | 5.76% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 42,360.0000 | 75,886,817 | 9.71% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 38,610.0000 | 75,886,817 | 5.46% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 36,610.0000 | 75,886,817 | 8.56% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 30,000.0000 | 75,886,817 | 11.11% | 0.00% |
| March 3, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 5125 | $14.40 | 34,424.0000 | 75,886,817 | 12.96% | 0.01% |
| March 3, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 700 | $15.13 | 33,724.0000 | 75,886,817 | 2.03% | 0.00% |
| Feb. 11, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Restricted Stock Units | 34300 | $0.00 | 34,300.0000 | 75,886,817 | 9999.99% | 0.05% |
| Feb. 11, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Employee Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 75,886,817 | 9999.99% | 0.10% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 254 | $20.33 | 39,549.0000 | 75,886,817 | 0.64% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 2557 | $19.81 | 39,803.0000 | 75,886,817 | 6.04% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 42,360.0000 | 75,886,817 | 9.71% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 38,610.0000 | 75,886,817 | 5.46% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 36,610.0000 | 75,886,817 | 8.56% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 33,750.0000 | 75,886,817 | 10.00% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 11,545.0000 | 75,886,817 | 20.00% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 10,000.0000 | 75,886,817 | 16.67% | 0.00% |
| Nov. 1, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3546 | $24.28 | 33,724.0000 | 72,779,381 | 9.51% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 33,888.0000 | 72,779,381 | 9.31% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 39,638.0000 | 72,779,381 | 10.45% | 0.01% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 2368 | $24.31 | 37,270.0000 | 72,779,381 | 5.97% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 14,431.0000 | 72,779,381 | 16.67% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 12,000.0000 | 72,779,381 | 14.29% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 37,500.0000 | 72,779,381 | 9.09% | 0.01% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 35,888.0000 | 72,779,381 | 5.90% | 0.00% |
| Aug. 26, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 20000 | $25.22 | 31,002.0000 | 54,337,901 | 39.21% | 0.04% |
| Aug. 1, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3377 | $21.43 | 51,102.0000 | 54,337,901 | 6.20% | 0.01% |
| Aug. 1, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 100 | $22.22 | 51,002.0000 | 54,337,901 | 0.20% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 51,219.0000 | 54,337,901 | 5.97% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 3750 | $0.00 | 41,250.0000 | 54,337,901 | 8.33% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 14,000.0000 | 54,337,901 | 12.50% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 17,317.0000 | 54,337,901 | 14.29% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 2490 | $20.67 | 54,479.0000 | 54,337,901 | 4.37% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 56,969.0000 | 54,337,901 | 7.05% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 53,219.0000 | 54,337,901 | 3.90% | 0.00% |
| June 20, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 20000 | $20.01 | 48,333.0000 | 54,337,901 | 29.27% | 0.04% |
| May 2, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3499 | $12.83 | 68,333.0000 | 54,337,901 | 4.87% | 0.01% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 20,203.0000 | 54,337,901 | 12.50% | 0.01% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 16,000.0000 | 54,337,901 | 11.11% | 0.00% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 1387 | $12.04 | 71,832.0000 | 54,337,901 | 1.89% | 0.00% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 73,219.0000 | 54,337,901 | 2.81% | 0.00% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 71,219.0000 | 54,337,901 | 4.22% | 0.01% |
| Feb. 16, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 6812 | $10.02 | 68,333.0000 | 54,337,901 | 9.07% | 0.01% |
| Feb. 13, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Employee Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 54,337,901 | 9999.99% | 0.28% |
| Feb. 13, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Restricted Stock Units | 45000 | $0.00 | 45,000.0000 | 54,337,901 | 9999.99% | 0.08% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 18,000.0000 | 54,337,901 | 10.00% | 0.00% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 23,089.0000 | 54,337,901 | 11.11% | 0.01% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 1671 | $7.99 | 75,145.0000 | 54,337,901 | 2.18% | 0.00% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 76,816.0000 | 54,337,901 | 2.67% | 0.00% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 74,816.0000 | 54,337,901 | 4.01% | 0.01% |
| Dec. 20, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 3541 | $10.00 | 71,930.0000 | 54,337,901 | 4.69% | 0.01% |
| Dec. 19, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 10906 | $10.00 | 75,471.0000 | 54,337,901 | 12.63% | 0.02% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 87,457.0000 | 48,607,990 | 2.34% | 0.00% |
| Oct. 31, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 1080 | $5.20 | 86,377.0000 | 48,607,990 | 1.23% | 0.00% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 25,975.0000 | 48,607,990 | 10.00% | 0.01% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 85,457.0000 | 48,607,990 | 3.50% | 0.01% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 20,000.0000 | 48,607,990 | 9.09% | 0.00% |
| July 31, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 1245 | $9.65 | 82,571.0000 | 48,607,990 | 1.49% | 0.00% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2000 | $0.00 | 22,000.0000 | 48,607,990 | 8.33% | 0.00% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 28,861.0000 | 48,607,990 | 9.09% | 0.01% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2000 | $0.00 | 83,816.0000 | 48,607,990 | 2.44% | 0.00% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 81,816.0000 | 48,607,990 | 3.66% | 0.01% |
| May 1, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 721 | $9.88 | 78,930.0000 | 48,607,990 | 0.91% | 0.00% |
| April 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 79,651.0000 | 48,607,990 | 3.76% | 0.01% |
| April 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 31,747.0000 | 48,607,990 | 8.33% | 0.01% |
| Feb. 14, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Restricted Stock Units | 24000 | $0.00 | 24,000.0000 | 48,607,990 | 9999.99% | 0.05% |
| Feb. 14, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | A | Employee Stock Option (right to buy) | 88900 | $0.00 | 88,900.0000 | 48,607,990 | 9999.99% | 0.18% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Common Stock | 2886 | $0.00 | 77,689.0000 | 48,607,990 | 3.86% | 0.01% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | M | Restricted Stock Units | 2886 | $0.00 | 34,633.0000 | 48,607,990 | 7.69% | 0.01% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | van Houte Hans | Chief Financial Officer | S | Common Stock | 924 | $11.78 | 76,765.0000 | 48,607,990 | 1.19% | 0.00% |